 |
|
A Study of Tor Kinase Inhibitor in Advanced Tumors
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase II, Phase I | Treatment | Active | 18 and over | D1600C00001
2008-002606-19, NCT00731263 |
Trial Description
Summary The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials. Eligibility Criteria Inclusion Criteria: - Histological or cytological confirmation of an advanced solid malignant tumour or lymphoma
- Cancer which is refactory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria) can be recruited
- Evidence of post-menopausal status or negative urine/serum pregnancy test for pre-menopausal female patients
Exclusion Criteria: - Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug.
- Patients with abnormal fasting glucose, have type I or II Diabetes or have uncontrolled blood fats and cholesterol
- Patients with a history of neurological disease, peripheral or central neuropathy, brain metastases or family history of myopathy are excluded
- Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions
Trial Contact Information
Trial Lead Organizations/Sponsors AstraZeneca Pharmaceuticals LP | Stanley Bernard Kaye | | Principal Investigator |
| Dr Carol Aghajanian | | Principal Investigator |
| Dr Aung Naing | | Principal Investigator |
Trial Sites
|
|
|
|
| U.S.A. |
|
| New York |
|
| |
New York |
|
| | | | | | | | | Research Site |
|
| Texas |
|
| |
Houston |
|
| | | | Research Site |
|
| United Kingdom |
|
| |
Sutton |
|
| | | | Research Site |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00731263
Information obtained from ClinicalTrials.gov on April 16, 2009 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
|
